文献速递妇科

激素受体表达模式界定子宫内膜样卵巢癌的临床意义亚组

Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma.
PubMed 文献 · Gynecol Oncol · 2019-09-05

该研究采用组织评分法(histoscore)评估107例WT1阴性子宫内膜样卵巢癌(EnOC)中孕激素受体(PR)、雌激素受体α(ER)和雄激素受体(AR)的表达,通过层次聚类识别出四个亚组,发现PR高表达组预后显著优于PR低表达组,且ER高表达者体重指数更高。

要点

  • 基于PR、ER和AR组织评分的层次聚类可将EnOC分为四个亚组。
  • PR+/ER+和PR+/ER-组疾病特异性生存优于PR-/ER+组(多变量HR均为0.05)。
  • II期PR高表达病例10年生存率为94.1%,PR低表达者为42.4%。

核心结论

  • PR高表达的子宫内膜样卵巢癌病例预后显著良好。
  • II期PR高表达EnOC可能是一线治疗降阶梯的候选人群。
  • 未来工作应致力于明确PR和ER阳性EnOC对内分泌治疗的敏感性。

研究设计与样本

  • 研究纳入107例WT1阴性子宫内膜样卵巢癌(EnOC)病例,采用组织评分法评估PR、ER和AR的核表达(结合阳性细胞比例与核染色强度)。

主要发现

  • 按PR、ER和AR组织评分进行层次聚类,识别出四个EnOC亚组:PR+/ER+、PR+/ER-、PR-/ER+和PR-/ER-。
  • II期PR高表达病例的10年生存率为94.1%,PR低表达病例为42.4%。
  • ER高表达EnOC患者(PR+/ER+和PR-/ER+)的体重指数高于ER低表达病例(P=0.015),也高于高级别浆液性卵巢癌患者(P<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Numerous studies have investigated the association between hormone receptor expression and clinical outcome in ovarian carcinoma (OC); however, these have largely focussed on serous OCs, with few studies reporting specifically on endometrioid OCs (EnOC). Where analyses have been stratified by histotype, expression has been assessed using the percentage of positive tumor cells, without accounting for nuclear expression intensity. METHODS: Here we assess the expression levels of progesterone receptor (PR), estrogen receptor alpha (ER) and androgen receptor (AR) using histoscore - a nuclear scoring method incorporating both proportion of positive cells and the intensity of nuclear staining - across a cohort of 107 WT1 negative EnOCs. RESULTS: Hierarchical clustering by PR, ER and AR histoscores identified four EnOC subgroups (PR+/ER+, PR+/ER-, PR-/ER+ and PR-/ER-). EnOC patients in the PR+/ER+ and PR+/ER- groups displayed favorable outcome (multivariable HR for disease-specific survival 0.05 [0.01-0.35] and 0.05 [0.00-0.51]) compared to the PR-/ER+ group. Ten-year survival for stage II PRhigh and PRlow cases was 94.1% and 42.4%. ERhigh EnOC patients (PR+/ER+, PR-/ER+) had higher body mass index compared to ERlow cases (P = 0.015) and high grade serous OC patients (P < 0.001). CONCLUSION: These data demonstrate that endometrioid OC cases with high PR expression display markedly favorable outcome. Stage II EnOCs with high PR expression represent potential candidates for de-escalation of first-line therapy. Future work should seek to characterise the sensitivity of PR and ER positive EnOCs to endocrine therapy.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Hollis RL, Stanley B, Iida Y, et al. Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma. Gynecol Oncol. 2019. PMID: 31495455. doi:10.1016/j.ygyno.2019.09.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。